Jasper Therapeutics Inc. announced positive updated clinical data from its BEACON Phase 1b/2a study and open label extension study evaluating briquilimab, a novel antibody therapy targeting KIT (CD117), in patients with chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). In the BEACON study, 83% of participants in the 240mg/180mg Q8W cohort achieved a complete response by week 3 after the initial dose, and 67% achieved a complete response at 12 weeks. In the open label extension study, 58% of CSU participants achieved a complete response at 12 weeks, and 75% achieved complete response or well controlled disease. KIT-related adverse events were low in frequency and predominantly low-grade. Jasper Therapeutics stated that these results provide sufficient data to inform dose selection for a planned Phase 2b study in CSU expected to begin in the second half of 2026. The company presented these results in a conference call and webinar, with presentation slides and webcast available on its Investor Relations website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622107-en) on January 08, 2026, and is solely responsible for the information contained therein.
Comments